GlassScriptPhysician profile
Ashley Rose Healy
NPI 1194230706
$4,952.63
in general payments reported to CMS, 2019-2025
27 companies · $931 in 2025
The $931 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $575 · 2022: $804 · 2023: $1,181 · 2024: $1,462 · 2025: $931.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,574.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,574.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,021.73 | 2021-2025 | |
| Novo Nordisk INC | $597.44 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $569.77 | 2021-2025 | Mounjaro, Jardiance |
| Otsuka America Pharmaceutical, INC. | $368.55 | 2022-2025 | Rexulti, Nuedexta |
| Astrazeneca Pharmaceuticals LP | $360.26 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $276.22 | 2021-2025 | Xifaxan |
| Lundbeck LLC | $246.15 | 2022-2024 | Rexulti |
| Axsome Therapeutics, INC. | $239.09 | 2023-2025 | Auvelity |
| Sumitomo Pharma America, INC. | $171.06 | 2023-2025 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $168.23 | 2021-2022 | |
| Astellas Pharma US INC | $157.87 | 2021-2024 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $134.70 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.01 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Pfizer INC. | $101.17 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $89.31 | 2021-2024 | Vaxneuvance, M-M-R II, Gardasil 9 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $67.71 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $62.10 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $41.12 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $32.22 | 2021 | |
| Dexcom, INC. | $20.70 | 2025 | Dexcom G6 Transmitter |
| Evoke Pharma, INC. | $20.57 | 2022 | |
| Fresenius USA Marketing, INC. | $19.33 | 2022 | |
| Sanofi Pasteur INC. | $14.81 | 2023 | |
| Abiomed | $14.47 | 2024 | Impella |
| Sanofi-Aventis U.S. LLC | $14.46 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.79 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $11.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Healy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.